HOME >> BIOLOGY >> NEWS
Discovering what genes do the high-throughput way

by the screen to characterize the effects of the RNAi treatment on the cells. They created a formal set of criteria to judge the cells consisting of seven classes of change that could have been induced. These included changes to cell number, shape, size and viability. Any changes were only considered significant if both scientists recorded them in replica experiments.

The researchers were also keen to find out if their method could be used to screen for genes that worked in, or inhibited specific molecular pathways. Screens in whole flies for genes that modify the effect of a particular genetic mutation have proved powerful, though time consuming. By adding two sets of double stranded RNA to each well, one that targeted the tumor suppressor gene pten and the other the gene to be tested, the researchers found that they were able to identify genes that modified the effects of inhibiting pten in cells. "These results demonstrate that modifier screens, as previously done in vivo, can be extended to RNAi screening methodology in cell culture", write the researchers.

Drug companies are becoming interested in this technique, as the rate-limiting step in cell-based drug discovery is finding out which protein is inhibited by a particular drug. Using Perrimon's method they can screen to see which gene, when inhibited, changes the cell in the same way as adding the drug.

"RNAi screens can complement classical Drosophila genetics to assign functions to both known and novel genes," write the researchers. "The same technology can be easily adapted to a wide variety of cell-based studies and a greater genomic scale."

Baum says, "The major difference between this and whole fly screens is that here we can be systematic. We can choose to look at any cell biological process and systematically test the set of genes that could be involved. In the future we will be able to screen the full genome in a few weeks, and look at any cell biological phenomenon.
'"/>

Contact: Gemma Bradley
press@biomedcentral.com
44-207-323-0323
BioMed Central
30-Sep-2003


Page: 1 2 3

Related biology news :

1. Discovering new regulators of the immune system
2. Discovering the Tree of Life
3. Discovering Virology From Beijerinck To Hyperlinks
4. "Discovering Biological Diversity" Is AAAS Topic For USGS Manager
5. Belgian researchers explore revolutionary approach to angiogenesis
6. Tracing genes, biologists show lizard migration is traced to Florida
7. Certain genes boost fish oils protection against breast cancer
8. Fossil genes reveal how life sheds form and function
9. Missing genes may help explain why plague bacteria are so deadly
10. Do genes respond to global warming?
11. Genetic map of important tree genes outlined

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Discovering what genes the high throughput way

(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4stcg3/india_sensors ... "India Sensors Market Forecast and Opportunities 2020" ... market is projected to grow at a CAGR ... automotive, industrial and healthcare sectors are the key ... addition, adoption of MEMS technology in sensors is ...
(Date:3/19/2015)... 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host Laura ... to pay, and ,a really big breakthrough in mobile payment.,  ...
(Date:3/17/2015)... 2015  MecklerMedia Corporation (OTCQX: MECK) announced its ... robots ever held in New York ... 11-13, 2015 at the Javits Convention Center. ... include: Acorn Product Development; Axis NJ; c-Link Systems; ... Littler; NewBotic Corporation; Neya Systems LLC; Reliabotics; RoboKind; ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
(Date:3/30/2015)... PMG Research, Benchmark Research, and ... formation of VaxCorps, a network of highly experienced, ... conduct of vaccine trials in healthy adult, elderly, ... successfully conducted over 500 phase I-III vaccine clinical ... influenza as well as a vast array of ...
(Date:3/30/2015)... IRVINE, Calif. , March 30, 2015 /PRNewswire/ ... that its subsidiary corporation, NuGene BioPharma, Inc. has ... board. Dr. Guan is an internationally ... After finishing his college education at Peking University, ... his Ph.D. degree from the University of North ...
(Date:3/30/2015)... ROCKVILLE, Md. , March 30, 2015 ... company dedicated to the acquisition, development and commercialization of ... for the global market with a commercial focus on ... China Food and Drug Administration (CFDA) has approved the ... trial in ovarian clear cell carcinoma (OCCC) patients for ...
(Date:3/30/2015)... 30, 2015  Spherix Incorporated (Nasdaq: SPEX ... fostering and monetization of intellectual property, today provided ... 3:13-cv-03494-M and  Spherix v. Uniden , Case No. ... for the Northern District of Texas ... v. Verizon, Case No. 1:14-cv-00721-GBL-TCB, in the ...
Breaking Biology Technology:PMG Research announces formation of VaxCorps with two industry-leading vaccine site networks 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 2Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 3
Cached News: